CN103142710B - Chinese medicinal composition for treating chronic prostatitis - Google Patents
Chinese medicinal composition for treating chronic prostatitis Download PDFInfo
- Publication number
- CN103142710B CN103142710B CN201310089172.6A CN201310089172A CN103142710B CN 103142710 B CN103142710 B CN 103142710B CN 201310089172 A CN201310089172 A CN 201310089172A CN 103142710 B CN103142710 B CN 103142710B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- chinese medicinal
- parts
- chronic prostatitis
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 241000218176 Corydalis Species 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims description 2
- 229940079593 drugs Drugs 0.000 claims 2
- 230000001737 promoting Effects 0.000 abstract description 10
- 210000003734 Kidney Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 Blood Anatomy 0.000 abstract description 5
- 208000004880 Polyuria Diseases 0.000 abstract description 5
- 210000000952 Spleen Anatomy 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 230000035619 diuresis Effects 0.000 abstract description 5
- 230000025627 positive regulation of urine volume Effects 0.000 abstract description 5
- 210000003932 Urinary Bladder Anatomy 0.000 abstract description 3
- 238000001035 drying Methods 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 abstract 1
- 240000000724 Berberis vulgaris Species 0.000 abstract 1
- 235000016068 Berberis vulgaris Nutrition 0.000 abstract 1
- 229940116229 Borneol Drugs 0.000 abstract 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 1
- 235000004310 Cinnamomum zeylanicum Nutrition 0.000 abstract 1
- 241000220457 Crotalaria Species 0.000 abstract 1
- 240000004559 Cuminum cyminum Species 0.000 abstract 1
- 235000007129 Cuminum cyminum Nutrition 0.000 abstract 1
- 235000002823 Mahonia aquifolium Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 241000208968 Securidaca Species 0.000 abstract 1
- 229930006709 borneol Natural products 0.000 abstract 1
- 235000017803 cinnamon Nutrition 0.000 abstract 1
- 231100000486 side effect Toxicity 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 240000000218 Cannabis sativa Species 0.000 description 6
- 210000002307 Prostate Anatomy 0.000 description 6
- 239000010977 jade Substances 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 210000001113 Umbilicus Anatomy 0.000 description 3
- 210000002700 Urine Anatomy 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- 210000004392 Genitalia Anatomy 0.000 description 2
- 229940067606 Lecithin Drugs 0.000 description 2
- 210000000265 Leukocytes Anatomy 0.000 description 2
- 210000002640 Perineum Anatomy 0.000 description 2
- 231100000614 Poison Toxicity 0.000 description 2
- 210000003708 Urethra Anatomy 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029578 entry into host Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002757 inflammatory Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 210000001015 Abdomen Anatomy 0.000 description 1
- 206010000269 Abscess Diseases 0.000 description 1
- 206010003549 Asthenia Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000668709 Dipterocarpus costatus Species 0.000 description 1
- 208000002173 Dizziness Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000006750 Hematuria Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022437 Insomnia Diseases 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 210000004705 Lumbosacral Region Anatomy 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 101710025181 SLC25A4 Proteins 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N Terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 Terazosin Drugs 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000249 desinfective Effects 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000003014 reinforcing Effects 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 230000001568 sexual Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Abstract
The invention discloses a Chinese medicinal composition for treating chronic prostatitis. According to the theory of traditional Chinese medicine, the chronic prostatitis attacks the bladder, is caused by the deficiency of the spleen and the kidney and has a symptom of downward flow of damp heat. Accordingly, the Chinese medicinal composition is prepared by drying the tangut barberry bark, the rough brake herb, the cinnamon, the cumin, the securidaca inappendiculata hassk, the rhizoma corydalis, the rust-brown crotalaria, the rhubarb and the borneol which are Chinese medicinal herbs having the efficacy of tonifying the spleen and the kidney, promoting blood circulation to remove blood stasis, clearing heat and promoting diuresis, grinding the Chinese medicinal herbs into powder, and mixing the power with 75% alcohol uniformly to obtain a paste to be applied on the navel. The clinical tests of the Hospital show that the Chinese medicinal composition achieves a total effective rate of 97.3% which is significantly higher than the total effective rate of a control group, has a small side effect and is worthy of clinical popularization and application.
Description
Technical field
Of the present inventionly relate to a kind of Chinese medicine composition, relate in particular to a kind of Chinese medicine composition for the treatment of chronic prostatitis.
Background technology
Chronic prostatitis is commonly encountered diseases, the frequently-occurring disease of Urology Surgery.Prostatitis is the crisscross pathological change that the prostatic inflammation that causes of Various Complex reason and inducement, immunity, neuroendocrine participate in, and causes the disease take urethral stimulant symptom and chronic pelvic pain as main clinical manifestation., can there is perineum, suprapubic region, inguinal region, genitals pain discomfort in prostatitic clinical manifestation variation; Urethral symptom has burn feeling, urgent micturition, frequent micturition, the pain of urinating when urinating, can be with terminal hematuria or the urethra purulent secretion of urinating; Actute infection can, with aversion to cold, heating, the General Symptoms such as weak, make a lot of antibiotic be difficult to enter in acinus and play a role, and the factor such as bacterial drug resistance in addition, therefore alone antibiotic therapy chronic prostatitis effect is not ideal.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine composition for the treatment of chronic prostatitis.The traditional Chinese medical science thinks that pathogenesis of chronic prostatitis mechanism is many by having a liking for food delicious food, leads to damp-heat in middle-JIAO, the multiple abscess part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels; Or exhaustion due to sexual indulgence do not save, asthenia of renal qi, the heresy of six climate exopathogens, the invasion of taking advantage of a weak point in opponent's defence, with the passing of time QI and blood stasis, undermines Liver and kidney; Its disease is at bladder, and it loses at spleen kidney two, and it is designated as damp invasion of lower energizer.Based on above understanding, the rule for the treatment of should be invigorating spleen and kidney, blood circulation promoting and blood stasis dispelling, clearing away heat-damp and promoting diuresis.Special because of prostate anatomical structure, conventional route of administration is difficult to prove effective, so adopt umbilicus to apply administration, effect is better.
The object of the invention is to be achieved through the following technical solutions, the Chinese medicine composition of this treatment chronic prostatitis is made up of the Chinese medicine of following weight portion: Cortex berberidis dasystachyae 3-6 part, Herba Pteridis multifidae 2-5 part, Cortex Cinnamomi 2-4 part, Fructus Foeniculi 3-5 part, Radix securidacae 4-6 part, Rhizoma Corydalis 1-3 part, sound tinkling of pieces of jade grass 3-6 part, Radix Et Rhizoma Rhei 1-2 part, Borneolum Syntheticum 0.5-1.5 part.
Preferably, 4 parts of Cortex berberidis dasystachyaes, 3 parts of Herba Pteridis multifidaes, 3 parts of Cortex Cinnamomis, 4 parts of Fructus Foeniculi, 5 parts of Radix securidacae, 2 parts of Rhizoma Corydalis, 4 parts of sound tinkling of pieces of jade grass, 1.5 parts of Radix Et Rhizoma Rhei, 1 part of Borneolum Syntheticum.
Preparation method is prepared above-mentioned Chinese medicine in proportion, dries and grinds into powder, mixes well with 75% ethanol, airtight for subsequent use.
In side: Cortex berberidis dasystachyae, Herba Pteridis multifidae heat clearing and damp drying, eliminating fire and detoxication, diuresis of blood circulation promoting; Cortex Cinnamomi, Fructus Foeniculi are mended fiery supporing yang, dispersing cold for relieving pain, regulating qi-flowing for harmonizing stomach, promoting the flow of QI-blood by warming the meridian; Radix securidacae, Rhizoma Corydalis promoting blood circulation to remove blood stasis, promoting the circulation of QI to relieve pain, clearing away heat and promoting diuresis; The Xiang Lingcao gas of astringing the lung, spleen reinforcing kidney, diuresis, detumescence poison; Radix Et Rhizoma Rhei heat and toxic materials clearing away, clearing away heat-fire, hemostasis removing toxic substances, blood circulation promoting and blood stasis dispelling; The Borneolum Syntheticum refreshment of having one's ideas straightened out, clearing heat for detumescence, pain relieving.
Clinical data
1, the selected 150 routine patients of physical data, are divided into treatment group and matched group, treatment group 75 examples, 25～60 years old age, average 43.2 years old at random; The course of disease 10 months～9 years, average 4.5 years; Married 60 examples; Matched group 75 examples, 23～55 years old age, average 40.1 years old; The course of disease 5 months～10 years, average 5.0 years; Married 65 examples; In above patient's symptom: urethral symptom refer to frequent micturition, urgent micturition, dysurea and the heeltap not to the utmost, drip after urine white; Local distending pain refers to perineal position distending pain or companion's lumbago and backache; General Symptoms finger is dizzy, weak, the symptoms such as insomnia.Two groups of cases, all through body of prostate ultrasound diagnosis, are used the EUB-26 of Hitachi type diasonograph, and result all cases all has echo change, skewness, and edge is irregular, prompting chronic prostatitis, all cases per rectum refers to inspection, all points out chronic prostatitis; Between two groups, age, the state of an illness, the course of disease, little etc. situation difference, has comparability.
2, diagnostic criteria was with reference to " the 3rd whole nation combination of Chinese and Western medicine andropathy scientific seminar of boundary " agreed standard in 1993, press 3 of hydraulic fluid (EPS) microscopies according to patient's medical history, clinical symptoms, prostate palpation, prostate, possessing 2 persons can make a definite diagnosis.Clinical symptoms: (1) paruria: urethral orifice adularescent mucoid secretions when frequent micturition, urgent micturition, dysurea, dribble of urine, urine end or stool, urethra scorching hot, scratchy and urinate not smooth (possessing more than 3); (2) local pain: perineum genital area, lower abdomen suprapubic region, lumbosacral region (at least one position continues more than 3 months).Prostate palpation (anus refers to inspection): Prostatic Surface injustice, or asymmetric, quality soft or hard inequality, maybe can touch inflammatory tubercle, has local tenderness.Prostate is by hydraulic fluid (EPS) microscopy: every high power field leukocyte exceedes more than 10, and lecithin reduces or disappears.
3, Therapeutic Method treatment group is used Chinese medicine composition of the present invention to apply umbilicus.Take Cortex berberidis dasystachyae 4g, Herba Pteridis multifidae 3g, Cortex Cinnamomi 3g, Fructus Foeniculi 4g, Radix securidacae 5g, Rhizoma Corydalis 2g, ring the tinkling of pieces of jade grass 4g, Radix Et Rhizoma Rhei 1.5g, Borneolum Syntheticum 1g, above-mentioned Chinese medicine is dried and ground into powder, mix well formation paste with 75% ethanol, before medication, first by umbilical part and surrounding skin routine disinfection, then get paste Chinese medicine composition, insert umbilical opening external Musk Analgesic Plaster and fix, after 24h, take off, ADT 1 time, was for 10 times 1 course for the treatment of, per course for the treatment of 7 days, interval; Matched group: 200 milligrams of oral hydrochloride levofloxacin tablets, every day 2 times; 2 milligrams of terazosin sheets, 1 time every night, two groups of each treatments 3 courses for the treatment of.
4, criterion of therapeutical effect, according to relevant chronic prostatitis criterion of therapeutical effect evaluation in " disease clinical diagnosis and criterion of therapeutical effect ", is cured: transference cure, and 3 massage liquid inspections are all normal, B ultrasonic and digital rectal examination normal; Take a turn for the better: symptom is improved, massage liquid checks 10/HP of leukocyte <, 10/HP of lecithin >, and pyocyte disappears, and B ultrasonic and digital rectal examination show that slight inflammatory changes; Invalid: treatment before and after symptom, check unchanged.
5, after 3 courses for the treatment of of (1) two group of therapeutic outcome treatment curative effect relatively in table 1.
Curative effect comparison after 3 courses for the treatment of of table 1 liang group treatment
With relatively P < 0.05 of matched group
Two groups of comparisons, treatment group cure rate, total effective rate, be obviously better than matched group, has significant, has comparability (P < 0.05).
The specific embodiment
Embodiment mono-: take Cortex berberidis dasystachyae 4g, Herba Pteridis multifidae 3g, Cortex Cinnamomi 3g, Fructus Foeniculi 4g, Radix securidacae 5g, Rhizoma Corydalis 2g, ring the tinkling of pieces of jade grass 4g, Radix Et Rhizoma Rhei 1.5g, Borneolum Syntheticum 1g.Above-mentioned Chinese medicine is dried and ground into powder, mix well with 75% ethanol, airtight for subsequent use.
Embodiment bis-: take Cortex berberidis dasystachyae 3g, Herba Pteridis multifidae 5g, Cortex Cinnamomi 2g, Fructus Foeniculi 5, Radix securidacae 6g, Rhizoma Corydalis 3g, ring the tinkling of pieces of jade grass 6g, Radix Et Rhizoma Rhei 2g, Borneolum Syntheticum 0.5g.Above-mentioned Chinese medicine is dried and ground into powder, mix well with 75% ethanol, airtight for subsequent use.
Embodiment tri-: take Cortex berberidis dasystachyae 6g, Herba Pteridis multifidae 2g, Cortex Cinnamomi 4g, Fructus Foeniculi 3g, Radix securidacae 4g, Rhizoma Corydalis 1g, ring the tinkling of pieces of jade grass 3g, Radix Et Rhizoma Rhei 1g, Borneolum Syntheticum 1.5g.Above-mentioned Chinese medicine is dried and ground into powder, mix well with 75% ethanol, airtight for subsequent use.
Claims (2)
1. a hilum applies the Chinese medicine composition of drug treatment chronic prostatitis, this Chinese medicine composition is made up of the Chinese medicine of following weight portion: Cortex berberidis dasystachyae 3-6 part, Herba Pteridis multifidae 2-5 part, Cortex Cinnamomi 2-4 part, Fructus Foeniculi 3-5 part, Radix securidacae 4-6 part, Rhizoma Corydalis 1-3 part, Herba Crotalariae Ferrugineae 3-6 part, Radix Et Rhizoma Rhei 1-2 part, Borneolum Syntheticum 0.5-1.5 part, preparation method is: above-mentioned Chinese medicine is prepared in proportion, dry and grind into powder, mix well with 75% ethanol, airtight for subsequent use.
2. a hilum according to claim 1 applies the Chinese medicine composition of drug treatment chronic prostatitis, and this Chinese medicine composition is made up of the Chinese medicine of following weight portion: 4 parts of Cortex berberidis dasystachyaes, 3 parts of Herba Pteridis multifidaes, 3 parts of Cortex Cinnamomis, 4 parts of Fructus Foeniculi, 5 parts of Radix securidacae, 2 parts of Rhizoma Corydalis, 4 parts of Herba Crotalariae Ferrugineaes, 1.5 parts of Radix Et Rhizoma Rhei, 1 part of Borneolum Syntheticum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310089172.6A CN103142710B (en) | 2013-03-07 | 2013-03-07 | Chinese medicinal composition for treating chronic prostatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310089172.6A CN103142710B (en) | 2013-03-07 | 2013-03-07 | Chinese medicinal composition for treating chronic prostatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103142710A CN103142710A (en) | 2013-06-12 |
| CN103142710B true CN103142710B (en) | 2014-05-28 |
Family
ID=48541219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310089172.6A Expired - Fee Related CN103142710B (en) | 2013-03-07 | 2013-03-07 | Chinese medicinal composition for treating chronic prostatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103142710B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108478691A (en) * | 2018-05-21 | 2018-09-04 | 盐城刘氏健康咨询有限公司 | It is a kind of to improve prostatitic navel cream and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1336213A (en) * | 2001-08-20 | 2002-02-20 | 邹勇 | Dysuria treating Chinese medicine 'Qinglongsan' and its prepn. |
| CN1436561A (en) * | 2002-02-08 | 2003-08-20 | 许建强 | Externally applied ointment for treating prostatosis and its prepn |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005225768A (en) * | 2004-02-10 | 2005-08-25 | Taisho Pharmaceut Co Ltd | Prophylactic or therapeutic agent for lower uropathy |
-
2013
- 2013-03-07 CN CN201310089172.6A patent/CN103142710B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1336213A (en) * | 2001-08-20 | 2002-02-20 | 邹勇 | Dysuria treating Chinese medicine 'Qinglongsan' and its prepn. |
| CN1436561A (en) * | 2002-02-08 | 2003-08-20 | 许建强 | Externally applied ointment for treating prostatosis and its prepn |
Non-Patent Citations (6)
| Title |
|---|
| JP特开2005-225768A 2005.08.25 |
| 中医药辩证治疗慢性前列腺炎的研究近况;覃兆伟;《中国医疗前沿》;20110531;第6卷(第9期);第14-15页 * |
| 包明蕙.卫睾丸.《老年百病验方》.上海中医药大学出版社,1996,(第1版),第207页. * |
| 张春林等，.单味凤尾草治疗前列腺炎.《黄河医学》.1994,第3卷(第4期),第56页. * |
| 汪毅等编.凤尾草.《苗族医药开发与临床应用》.新疆科学技术出版社,2003,(第1版),第245-246页. * |
| 覃兆伟.中医药辩证治疗慢性前列腺炎的研究近况.《中国医疗前沿》.2011,第6卷(第9期),第14-15页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103142710A (en) | 2013-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100531768C (en) | Medicament for treating chronic prostatitis and prostatic hyperplasia | |
| CN104398640A (en) | Traditional Chinese medicinal composition for treating prostatitis, and preparation method thereof | |
| CN103800622A (en) | Traditional Chinese medicament for treating prostatitis | |
| Liu et al. | Applications and therapeutic actions of complementary and alternative medicine for women with genital infection | |
| CN102526398A (en) | Externally-used traditional Chinese medicinal preparation for treating chronic pelvic inflammation | |
| CN103599472B (en) | A kind of Chinese medicine composition being used for the treatment of prostatic hyperplasia | |
| CN103599323B (en) | Traditional Chinese medicinal composition for treating prostatitis | |
| CN103083452A (en) | Traditional Chinese medicine for treating chronic bacterial prostatitis | |
| CN109331130A (en) | The traditional Chinese medicine for outer use for treating hemorrhoid | |
| CN103933171B (en) | A kind of External apply medicinal wine for the treatment of lumbago and skelalgia | |
| CN103142710B (en) | Chinese medicinal composition for treating chronic prostatitis | |
| CN102614487A (en) | Plaster for treatment of prostate and uracratia | |
| CN101797308B (en) | External medicine for treating mastitis | |
| CN102872416B (en) | Traditional Chinese medicine sitting lotion for treating chronic prostatitis | |
| CN102600272A (en) | Traditional Chinese medicine for treatment of orthopedic disease | |
| CN103083617A (en) | Traditional Chinese medicine for treating hyperplasia of prostate | |
| CN104274664A (en) | Traditional Chinese medicine composition for treating prostatitis by umbilical applied administration and preparation method thereof | |
| CN104435913A (en) | Traditional Chinese medicine composition for treating prostatitis | |
| CN104840783A (en) | Traditional Chinese medicine preparation for treating urinary calculus and preparation method of traditional Chinese medicine preparation | |
| CN103330793B (en) | Traditional Chinese medicine enema for treating chronic pelvic inflammatory disease | |
| CN103736014A (en) | Chinese medicinal composition for treating prostatic hyperplasia | |
| CN103007186A (en) | Chinese medicinal formulae used for treating increase of jaundice | |
| CN103446277B (en) | Traditional Chinese medicine composition for treating prostatitis by fumigating | |
| CN102526254B (en) | Traditional Chinese medicine composition for treating male prostatitis | |
| CN104288707A (en) | Traditional Chinese medicinal composition for treating pelvic inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHANG YUQI Free format text: FORMER OWNER: QIN JUN Effective date: 20140317 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Yuqi Inventor after: Zhang Shiqin Inventor before: Qin Jun |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 276300 LINYI, SHANDONG PROVINCE TO: 276000 LINYI, SHANDONG PROVINCE Free format text: CORRECT: INVENTOR; FROM: QIN JUN TO: ZHANG YUQI ZHANG SHIQIN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140317 Address after: 42 people's Hospital of Lanshan District, Lanshan street, Lanshan District, Shandong, Linyi 276000, Linyi Applicant after: Zhang Yuqi Address before: 276300 Yinan County People's Hospital of Yinan, Shandong Province, Lishan Road, No. 50, Linyi Applicant before: Qin Jun |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140528 Termination date: 20150307 |
|
| EXPY | Termination of patent right or utility model |